Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1979 2
1980 1
1981 1
1984 1
1985 2
1986 5
1987 4
1988 4
1989 7
1990 10
1991 9
1992 7
1993 6
1994 16
1995 19
1996 13
1997 17
1998 12
1999 23
2000 23
2001 26
2002 26
2003 49
2004 40
2005 53
2006 64
2007 60
2008 58
2009 88
2010 82
2011 99
2012 110
2013 123
2014 139
2015 128
2016 117
2017 107
2018 133
2019 134
2020 170
2021 145
2022 145
2023 145
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

2,110 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Lung Non-Small Cell Carcinoma"
Page 1
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Ettinger DS, et al. J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025. J Natl Compr Canc Netw. 2022. PMID: 35545176
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. P …
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide r …
Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, Wu S, Qiu F, Peng D, Zhu X, Chuai S, Beck S, Kanu N, Carbone D, Zhang Z, Wang J. Chen K, et al. Cancer Cell. 2023 Oct 9;41(10):1749-1762.e6. doi: 10.1016/j.ccell.2023.08.010. Epub 2023 Sep 7. Cancer Cell. 2023. PMID: 37683638
PROPHET and state-of-the-art fixed-panel assays were applied to 760 plasma samples from 181 prospectively enrolled early stage non-small cell lung cancer patients. PROPHET shows higher sensitivity of 45% at baseline with circulating tumor DNA (ctDNA). …
PROPHET and state-of-the-art fixed-panel assays were applied to 760 plasma samples from 181 prospectively enrolled early stage non- …
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Ettinger DS, et al. J Natl Compr Canc Netw. 2017 Apr;15(4):504-535. doi: 10.6004/jnccn.2017.0050. J Natl Compr Canc Netw. 2017. PMID: 28404761
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. ...
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and …
Molecular Pathology of Primary Non-small Cell Lung Cancer.
Suster DI, Mino-Kenudson M. Suster DI, et al. Arch Med Res. 2020 Nov;51(8):784-798. doi: 10.1016/j.arcmed.2020.08.004. Epub 2020 Aug 29. Arch Med Res. 2020. PMID: 32873398 Review.
Of all cancer types to affect the pulmonary system, non-small cell lung carcinoma comprises approximately 80-85% of all tumors. ...Numerous different testing modalities, with various strengths and limitations now exist which complicate diagnosti …
Of all cancer types to affect the pulmonary system, non-small cell lung carcinoma comprises approximately …
Cryoablation for T1N0M0 non-small cell lung cancer using liquid nitrogen.
Nomori H, Yamazaki I, Shiraishi A, Adachi T, Kanno M. Nomori H, et al. Eur J Radiol. 2020 Dec;133:109334. doi: 10.1016/j.ejrad.2020.109334. Epub 2020 Oct 22. Eur J Radiol. 2020. PMID: 33152627
OBJECTIVES: To evaluate local control and complications of cryoablation for T1N0M0 non-small cell lung cancer using liquid nitrogen. METHODS: This is a retrospective observational study on 101 patients with T1N0M0 NSCLC who underwent cryoablation betwe …
OBJECTIVES: To evaluate local control and complications of cryoablation for T1N0M0 non-small cell lung cancer us …
Non-small cell lung cancer.
Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM; NCCN (National Comprehensive Cancer Network). Ettinger DS, et al. J Natl Compr Canc Netw. 2012 Oct 1;10(10):1236-71. doi: 10.6004/jnccn.2012.0130. J Natl Compr Canc Netw. 2012. PMID: 23054877
Most patients with non-small cell lung cancer (NSCLC) are diagnosed with advanced cancer. ...
Most patients with non-small cell lung cancer (NSCLC) are diagnosed with advanced cancer. ...
Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives.
Schegoleva AA, Khozyainova AA, Fedorov AA, Gerashchenko TS, Rodionov EO, Topolnitsky EB, Shefer NA, Pankova OV, Durova AA, Zavyalova MV, Perelmuter VM, Denisov EV. Schegoleva AA, et al. Cell Physiol Biochem. 2021 Mar 10;55(S2):29-48. doi: 10.33594/000000340. Cell Physiol Biochem. 2021. PMID: 33687819 Free article. Review.
Despite advances in diagnostics and therapy of non-small cell lung cancer (NSCLC), the problem of prognosis and prevention of tumor progression is still highly important. ...In conclusion, we highlight the importance of further studies to reveal molecu …
Despite advances in diagnostics and therapy of non-small cell lung cancer (NSCLC), the problem of prognosis and …
The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications.
Zheng H, Zhan Y, Liu S, Lu J, Luo J, Feng J, Fan S. Zheng H, et al. J Exp Clin Cancer Res. 2018 Sep 14;37(1):226. doi: 10.1186/s13046-018-0901-5. J Exp Clin Cancer Res. 2018. PMID: 30217217 Free PMC article. Review.
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, and it is one of the leading causes of cancer death in both men and women worldwide due to diagnosis in the advanced stage, rapid metastasis, and recurren …
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, and it is one of …
Surveillance of resected non-small cell lung cancer.
López-González A, Ibeas Millán P, Cantos B, Provencio M. López-González A, et al. Clin Transl Oncol. 2012 Oct;14(10):721-5. doi: 10.1007/s12094-012-0841-z. Epub 2012 Jul 21. Clin Transl Oncol. 2012. PMID: 22855136 Review.
Lung cancer is the most common cancer in the world. 15 % of all patients with lung cancer are diagnosed at an early stage, and surgery is the treatment of choice for them. 40 % of all patients survive more than 5 years after surgery, and most of them die as a result …
Lung cancer is the most common cancer in the world. 15 % of all patients with lung cancer are diagnosed at an early stage, and …
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM. Aggarwal C, et al. Lung Cancer. 2021 Dec;162:42-53. doi: 10.1016/j.lungcan.2021.09.003. Epub 2021 Sep 15. Lung Cancer. 2021. PMID: 34739853 Free article. Review.
Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of targeted therapies for advanced disease and concomitant molecular testing to inform clinical decision-making. ...In this review, we consider th …
Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of tar …
2,110 results